Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeShare-based CompensationShare-based CompensationShares Issued
Growth Metrics
Income Statement
Others
Ratios

Avidity Biosciences, Inc. (RNA) Other financing activities (2020 - 2022)

Avidity Biosciences' Other financing activities history spans 3 years, with the latest figure at -$1.9 million for Q3 2022.

  • For Q3 2022, Other financing activities fell 118.57% year-over-year to -$1.9 million; the TTM value through Sep 2022 reached $863000.0, down 91.7%, while the annual FY2021 figure was $11.3 million, 53.13% down from the prior year.
  • Other financing activities reached -$1.9 million in Q3 2022 per RNA's latest filing, down from $1.2 million in the prior quarter.
  • In the past five years, Other financing activities ranged from a high of $22.5 million in Q2 2020 to a low of -$1.9 million in Q3 2022.
  • Average Other financing activities over 3 years is $3.9 million, with a median of $863000.0 recorded in 2021.
  • The largest YoY upside for Other financing activities was 11740.0% in 2022 against a maximum downside of 118.57% in 2022.
  • A 3-year view of Other financing activities shows it stood at $1.3 million in 2020, then tumbled by 35.88% to $863000.0 in 2021, then plummeted by 323.52% to -$1.9 million in 2022.
  • Per Business Quant, the three most recent readings for RNA's Other financing activities are -$1.9 million (Q3 2022), $1.2 million (Q2 2022), and $745000.0 (Q1 2022).